Broughton E, Bektas M, Colosia A, Kuper K, Fernandez MM, Al-Taie A, Kotb R. A systematic literature review of the epidemiology of complicated urinary tract infection. Infect Dis Ther. 2025 Apr 24. doi: 10.1007/s40121-025-01149-8
La EM, Sweeney C, Davenport E, Calhoun S, Harmelink A, Singer D. Healthcare professionals' knowledge, attitudes, and practices regarding respiratory syncytial virus disease and vaccination in adults aged 60 years and older. Infect Dis Ther. 2025 Apr;14(4):735-52. doi: 10.1007/s40121-025-01119-0
Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, Enoch DA, Gruener B, Herbrecht R, Lahmer T, Lortholary O, Melenotte C, De Rosa FG, Garcia-Vidal C, Jimenez M, Fernandez M, Cornely O. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024 Dec;13(12):2527-43. doi: 10.1007/s40121-024-01064-4
Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Apr;13(4):827-44. doi: 10.1007/s40121-024-00939-w
Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of five pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023 Jul;12(7):1809-21. doi: 10.1007/s40121-023-00828-8
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C, Wilson M. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States. Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4
Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman DM. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021 Jul 12. doi: 10.1007/s40121-021-00485-9
Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Sacco P, Myers K, Poulos C, Sweeney C, Hollis K, Snow V, Vietri JT. Preferences for adult pneumococcal vaccine recommendations among United States health care providers. Infect Dis Ther. 2019 Dec;8(4):657-70. doi: 10.1007/s40121-019-00266-5
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Basarir H, Brockbank J, Knight C, Wolowacz S. The inclusion of the utility values for carers and family members in HTAs: a case study of recent NICE appraisals in the UK. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA. [abstract] Value in Health Regional Issues. 2019 May; 22(Suppl 2):S330.
Wasserman MD, Sings HL, Wilson MR, Postma MJ, Breton MC, McDade C, Farkouh RA. Re-analysis of modeling a switch from a 13-valent to 10-valent pneumococcal conjugate vaccine in Canada: leveraging real-world experience from Belgium. Infect Dis Ther. 2019 Mar;8(1):1-3. doi: 10.1007/s40121-018-0222-1
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017 Dec;6(4):477-86. doi: 10.1007/s40121-017-0167-9
Winnette R, Zárate V, Machnicki G, DeMuro-Mercon C, Gawlicki M, Gnanasakthy A. Patient-reported outcomes in Latin America: implementation in research and role in emerging HTA systems. Value in Health Regional Issues. 2015 Dec;8:49-55. doi: 10.1016/j.vhri.2015.03.008
Hogue S, Hollis K, Silvia S, Wooddell M. The EpiPen4Schools® survey: staff training and use of epinephrine auto-injectors for the treatment of anaphylaxis in large US school districts. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. [abstract] Value in Health Regional Issues. 2015 Nov; 18(7):A505. doi: 10.1016/j.jval.2015.09.1441